Concepts (71)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdomyosarcoma | 3 | 2024 | 229 | 0.920 |
Why?
|
| Hematuria | 1 | 2025 | 48 | 0.870 |
Why?
|
| Sarcoma, Ewing | 1 | 2025 | 119 | 0.810 |
Why?
|
| Palliative Care | 2 | 2024 | 443 | 0.770 |
Why?
|
| Fibroma | 1 | 2022 | 29 | 0.740 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2022 | 50 | 0.720 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2022 | 124 | 0.670 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 139 | 0.650 |
Why?
|
| Terminal Care | 1 | 2021 | 116 | 0.620 |
Why?
|
| Bone Neoplasms | 1 | 2025 | 472 | 0.620 |
Why?
|
| Sarcoma | 1 | 2022 | 218 | 0.620 |
Why?
|
| Iron | 1 | 2022 | 305 | 0.610 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2017 | 10 | 0.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 1313 | 0.520 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2017 | 49 | 0.520 |
Why?
|
| Neoplasms | 2 | 2023 | 2951 | 0.520 |
Why?
|
| Acute Kidney Injury | 1 | 2025 | 695 | 0.520 |
Why?
|
| Carcinoma | 1 | 2017 | 283 | 0.450 |
Why?
|
| Perioperative Care | 2 | 2025 | 221 | 0.330 |
Why?
|
| Child | 7 | 2024 | 26075 | 0.260 |
Why?
|
| Life Support Care | 1 | 2025 | 52 | 0.230 |
Why?
|
| Ifosfamide | 1 | 2025 | 26 | 0.220 |
Why?
|
| Camping | 1 | 2024 | 14 | 0.220 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 41 | 0.190 |
Why?
|
| Humans | 13 | 2025 | 130255 | 0.190 |
Why?
|
| Resuscitation | 1 | 2025 | 275 | 0.190 |
Why?
|
| Shock | 1 | 2023 | 97 | 0.180 |
Why?
|
| Neoplasms, Second Primary | 1 | 2024 | 140 | 0.180 |
Why?
|
| Proportional Hazards Models | 2 | 2023 | 1389 | 0.180 |
Why?
|
| Medical Oncology | 1 | 2023 | 240 | 0.170 |
Why?
|
| Hemoglobins | 1 | 2022 | 285 | 0.170 |
Why?
|
| Heart Arrest | 1 | 2025 | 376 | 0.170 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2020 | 15 | 0.160 |
Why?
|
| Communication | 1 | 2023 | 539 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2022 | 597 | 0.140 |
Why?
|
| Repressor Proteins | 1 | 2022 | 760 | 0.140 |
Why?
|
| Recovery of Function | 1 | 2020 | 444 | 0.140 |
Why?
|
| Survival Rate | 1 | 2022 | 2110 | 0.130 |
Why?
|
| Genes, p53 | 1 | 2017 | 207 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2020 | 408 | 0.130 |
Why?
|
| Neoplasm Grading | 1 | 2017 | 273 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2022 | 705 | 0.120 |
Why?
|
| Parents | 1 | 2023 | 1106 | 0.120 |
Why?
|
| Societies, Medical | 1 | 2020 | 796 | 0.120 |
Why?
|
| Electroencephalography | 1 | 2020 | 846 | 0.110 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 372 | 0.110 |
Why?
|
| Incidence | 1 | 2022 | 3315 | 0.110 |
Why?
|
| Pediatrics | 1 | 2024 | 1243 | 0.110 |
Why?
|
| Emergency Service, Hospital | 1 | 2022 | 1215 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2022 | 14937 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 1583 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 1217 | 0.100 |
Why?
|
| Prognosis | 1 | 2023 | 4854 | 0.100 |
Why?
|
| Germ Cells | 2 | 2024 | 199 | 0.090 |
Why?
|
| Infant | 2 | 2023 | 13229 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2062 | 0.080 |
Why?
|
| United States | 2 | 2022 | 11838 | 0.080 |
Why?
|
| Female | 4 | 2024 | 70265 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3746 | 0.060 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12829 | 0.060 |
Why?
|
| Adolescent | 1 | 2022 | 20708 | 0.050 |
Why?
|
| Mediator Complex | 1 | 2023 | 62 | 0.050 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2025 | 322 | 0.040 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 359 | 0.040 |
Why?
|
| Male | 2 | 2024 | 64350 | 0.040 |
Why?
|
| Anesthesia, General | 1 | 2020 | 142 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 530 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2024 | 1098 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2023 | 1822 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5047 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6436 | 0.020 |
Why?
|